Navigation Links
TOPICA Pharmaceuticals Announces Sublicensing Agreement for Tinea Indication

PALO ALTO, Calif., Sept. 21 /PRNewswire/ -- TOPICA Pharmaceuticals, Inc. a privately-held biotechnology company, today announced that it has entered into a sublicense and purchase option agreement with an undisclosed partner to develop luliconazole exclusively for tinea infections of the skin in the Americas and Europe. By agreement, additional terms of the deal were not disclosed.

In conjunction with the sublicensing agreement, TOPICA Pharmaceuticals will now focus on developing luliconazole exclusively for the treatment of onychomycosis.  In February of 2010 the company's IND for onychomycosis was opened, paving the way for human clinical trials to begin later in 2010.  

"We are looking forward to the initiation of luliconazole's clinical development program this fall and validating the molecule's promising preclinical profile in onychomycosis.  If the molecule's preclinical profile is validated, luliconazole has the potential to be the first truly effective, safe and convenient topical therapy for onychomycosis; providing physicians and patients with a much needed alternative to currently available oral anti-fungal therapies that have risk of serious adverse events," said Greg Vontz, president & CEO of TOPICA Pharmaceuticals.  

"This is a unique and well aligned transaction that will help to maximize the future potential of the molecule by partnering luliconazole with a well resourced partner and then advancing the molecule in a dedicated effort focused on resolving a long-standing medical need by providing an effective and safe topical therapy for onychomycosis," said Alex Barkas, TOPICA board member and managing director of Prospect Venture Partners.  "We are pleased with the arrangement and the shareholder value we believe will result." TOPICA's existing investors will lead an additional financing for the onychomycosis company.

About Luliconazole

Luliconazole is one of the most potent and broad-spectrum topical antifungal agents. Going forward TOPICA Pharmaceuticals will be developing luliconazole for onychomycosis, which affects approximately 35 million people in the U.S. Currently approved therapies for onychomycosis are either marginally effective or are complicated by the potential of liver toxicity and require hepatic monitoring.  In numerous rigorous preclinical models of onychomycosis, luliconazole has demonstrated rapid penetration and therapeutically effective levels in the nail bed.  This preclinical profile suggests luliconazole has the potential to be the first highly effective and safe topical therapy for onychomycosis.   The potential annual U.S. market for onychomycosis treatment is estimated at approximately $3 billion.  

TOPICA has an exclusive license from Nihon Nohyaku Co., Ltd. to develop and market luliconazole for onychomycosis in the Americas and Europe.

About TOPICA Pharmaceuticals, Inc.

TOPICA Pharmaceuticals, Inc. is a privately-held specialty pharmaceutical company focused on licensing, developing and commercializing topical prescription products to treat the needs of patients with serious nail and skin conditions. Taking advantage of its established trans-Pacific network of scientific and industry contacts, TOPICA has in-licensed its lead product candidate, luliconazole, a topical antifungal agent that is already on the market in Japan. TOPICA has been developing luliconazole for the treatment of tinea pedis (athlete's foot) which will now be developed by an undisclosed partner pursuant to a sublicense agreement.  Going forward, TOPICA will be focused on onychomycosis (fungal infections of the nail). For more information, please visit

SOURCE TOPICA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
2. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
3. Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds
4. Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R)
5. Topical erectile dysfunction therapy shows promise
6. Hygeia Therapeutics Signs an Exclusive License with Yale University for Potent, Safe Topical Anti-Androgens
7. Innocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL for the Treatment and Prevention of Diabetic Foot Infections
8. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
9. Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain
10. Pilot Study Finds Adding Topical Imiquimod To Laser Therapy Improves The Response Of Port Wine Stain Birthmarks
11. Sigma-Aldrich Signs Exclusive Agreement With IsoSciences, LLC, to Distribute Isotopically Labeled Bioactive Compounds
Post Your Comments:
(Date:10/12/2017)... ... , ... AMRI, a global contract research, development and manufacturing ... and quality of life, will now be offering its impurity solutions as a ... requirements for all new drug products, including the finalization of ICH M7 earlier ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is ... and 8th June 2018 in San Francisco, CA. The Summit brings together current and ... distinguished CEOs, board directors and government officials from around the world to address key ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study ... in frozen and fresh in vitro fertilization (IVF) transfer cycles. The ... IVF success. , After comparing the results from the fresh and frozen transfer ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Rotary Club. The event entitled “Stem Cells and Their Regenerative Powers,” ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, ...
Breaking Biology Technology:
(Date:4/5/2017)... YORK , April 5, 2017 Today ... is announcing that the server component of the HYPR ... known for providing the end-to-end security architecture that empowers ... HYPR has already secured over 15 million ... makers including manufacturers of connected home product suites and ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
Breaking Biology News(10 mins):